

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 June 2006 (01.06.2006)

PCT

(10) International Publication Number  
**WO 2006/056783 A2**

(51) International Patent Classification:

A61K 31/683 (2006.01) A61P 25/28 (2006.01)  
A61K 31/685 (2006.01) A61P 25/16 (2006.01)  
A61P 37/02 (2006.01)

(74) Agent: DOLAN, Anthony, Patrick; BTG INTERNATIONAL LIMITED, 10 Fleet Street, Limeburner Lane, London EC4M 7SB (GB).

(21) International Application Number:

PCT/GB2005/004516

(22) International Filing Date:

25 November 2005 (25.11.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0425932.1 25 November 2004 (25.11.2004) GB

(71) Applicant (for all designated States except US): BTG INTERNATIONAL LIMITED [GB/GB]; 10 Fleet Place, Limeburner Lane, London EC4M 7SB (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HARBIGE, Laurence, S. [GB/GB]; The University of Greenwich, Woolwich Campus, Wellington Street, London SE18 6PF (GB). LEACH, Michael, J. [GB/GB]; The University of Greenwich, Woolwich Campus, Wellington Street, London SE18 6PF (GB). SHARIEF, Mohammed [GB/GB]; Dept. of Clinical Neurosciences, Guy's, King's & St Thomas's School of Medicine, Hodgkin Building, Guy's Hospital, London SE1 9RT (GB). BARRACLOUGH, Paul [GB/GB]; 27 Sevington Park, Maidstone, Kent ME15 9SB (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STRUCTURED PHOSPHOLIPIDS

(57) Abstract: A method of treating a patient in need of therapy for a disease in which cytokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterified with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of  $\gamma$ -linolenoyl, dihomog- $\gamma$ -linolenoyl acid and arachidonoyl.



WO 2006/056783 A2

## STRUCTURED PHOSPHOLIPIDS

The present invention relates to a method for modulating cytokine levels in subjects suffering from diseases in which these have become dysregulated or are otherwise capable of modulation to provide therapeutic benefit. Particularly is provided a method for modulating transforming growth factor  $\beta$  (TGF- $\beta$ ), particularly TGF- $\beta$ 1, but also cytokines TNF- $\alpha$  and IL-1 $\beta$ , still more preferably for maintaining and/or restoring cytokine balance where imbalance is found in diseases of the immune system and in neurodegeneration. Such diseases include multiple sclerosis and various autoimmune states.

More particularly the present invention provides treatment for neurodegenerative conditions, particularly those such as demyelinating diseases, such as multiple sclerosis, Alzheimer's and Parkinson's diseases and the degenerative sequelae associated with head trauma, stroke and intracranial bleeds, whereby neuronal function may be improved or restored from an impaired condition, eg. by remyelination.

Further provided are novel use of known and novel compounds comprising unsaturated fatty acid moieties for the manufacture of medicaments capable of effectively treating such conditions, more particularly being capable of achieving previously unattained levels of success with regard to maintenance and recovery of neurological function.

It is well reported in the literature that essential fatty acids (EFAs) of the n-3 and n-6 unsaturation pattern have beneficial effect in a wide variety of human physiological disorders, including autoimmune disease (WO 02/02105). Harbige (1998) Proc. Nut. Soc. 57, 555-562 reviewed the supplementation of diet with n-3 and n-6 acids in autoimmune disease states, and particularly noted evidence of benefit of  $\gamma$ -linolenic (GLA) and/or linoleic acid (LA) rich oils. Harbige (2003) Lipids Vol 38, no 4 discusses broader implications for the immune system and the mechanisms whereby high LA supplementation might cause production of pro-inflammatory states.

The inventor's copending unpublished patent application PCT/GB2004/002089 and PCT/GB2004/003524, incorporated herein by reference, relate to the use of synthetic, plant and fungal oils for the treatment of

neurodegenerative diseases, particularly multiple sclerosis, stroke, head trauma, Alzheimer's and Parkinson's disease. PCT/GB2004/002089 relates to oils characterised by having at high percentages of the essential fatty acid  $\gamma$ -linolenic acid (GLA) at the sn-2 position of their lipids, typically being over 40% of the sn-2 fatty acid total of the oil. PCT/GB2004/003524 relates to structured lipids having an sn-2 fatty acid residue selected from  $\gamma$ -linolenic acid (GLA), dihomo- $\gamma$ -linolenic acid (DHGLA) and arachidonic acid (AA).

These applications report remarkable levels of success in treating animal model CREAE and human relapse remitting multiple sclerosis. When triglyceride oils containing suitable levels of these fatty acids in the sn-2 position are administered to patients over a period of several months the inventors have determined an associated therapeutic increase in TGF- $\beta$ 1 and decrease in TNF- $\alpha$  and IL-1 $\beta$ , as measured as spontaneously released from Peripheral Blood Mononuclear Cells (PBMC) isolated from a patient's blood.

The present inventors unpublished work, described in the aforesaid PCT applications, has indicated that the position of the  $\gamma$ -linolenic acid, dihomo- $\gamma$ -linolenic acid and arachidonic acid in a glyceride is of great significance in determining its activity in modulating cytokines and in correcting metabolic defect in multiple sclerosis and other demyelinating disease. Whereas sn-1 and sn-3 position fatty acids appear to have very little therapeutic significance, the sn-2 position is critical to the activity of the triglyceride.

The prior art does not appear to recognise this crucial fact, with consequences of failure in all previous studies. Table 3 of EP 0520624 (Efamol Holdings) compares the triglyceride content of Evening Primrose and Borage Oils, the former being taught to be more therapeutically effective than the latter for a variety of GLA responsive disorders. This document indicates Borage oil to have at least twenty seven different triglyceride components, only 20% by weight of which have sn-2 GLA. Page 3, lines 40-42 notes that biological testing has shown that equal amounts of GLA may indeed have very different effects when that GLA is supplied as different oil sources. Crucially, it then directs the reader to one particular fraction present in Evening Primrose Oil (EPO), but not Borage Oil, as being responsible for the former's superior effect in raising PGE<sub>1</sub> (see EP 0520624 Chart page 4 and Table 2) and thus the anti-inflammatory effect: that fraction being identified as di-linoleoyl-mono-

gamma-linolenyl-glycerol (DLMG) which it states to be 18 to 19% of the total triglyceride in EPO. Critically, page 6 clearly teaches that the position of the GLA, in sn-1, 2 or 3, is not important to this effect.

5 Dines et al (1994) Proceedings of the Physiological Society, Aberdeen Meeting 14-16 September 1994 report on studies of treatment of diabetic neuropathy neuronal damage with  $\gamma$ -linolenic acid containing oils of the type advocated by EP 0520624 and again note that Borage Oil was not very effective in treating this neurodegeneration whereas Evening primrose oil was. The paper concludes that Borage Oil contains other constituents that interfere with GLA activity.

10 Bates et al noted that lipid oils comprising a mixture of linoleic acid and  $\gamma$ -linolenic acid residues had been suggested back in 1957 to be possibly more efficacious in treating inflammation and autoimmune diseases, but found that at 3g oil per day (Naudicelle Evening Primrose oil 7:1 LA:GLA), patients who had relapses became more ill on the trial oil than on the control.

15 Although the aetiology of multiple sclerosis (MS) remains unknown, studies have shown that MS patients have higher than normal neuro-antigen autoreactive T-cells levels. These T-cells react *inter alia* to myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) and are in an increased state of activation compared with healthy controls. The actual processes of axonal damage e.g. chronic  
20 inflammation, demyelination and astrogliosis in MS is complex, but white matter inflammation and demyelination are considered to determine disease severity, whilst recent studies suggested that axonal damage in MS begins in the early stages of the disease and contributes to disability (De Stefano et al, 2001).

Experimental autoimmune encephalomyelitis (EAE) is the most frequently  
25 used animal model for immune mediated effects of MS. Studies in the guinea-pig have shown that linoleic acid partially suppresses the incidence and severity of EAE (Meade et al (1978)). (Harbige et al (1995), 1997b) demonstrated disease modifying effects of linoleic acid and  $\gamma$ -linolenic acid on clinical and histopathological manifestations of EAE. Depending on dose,  $\gamma$ -linolenic acid was fully protective in  
30 acute rat EAE whereas linoleic acid had dose-dependent action on the clinical severity but did not abolish it.

Despite these experimental findings, it is recognised that the human disease, multiple sclerosis, is highly complex and can be conversely exacerbated and

ameliorated by the activity of T-cells and other immune response factors. It is thought that the n-6 fatty acids promote autoimmune and inflammatory disease based upon results obtained with linoleic acid only. TGF- $\beta$ 1 and PGE<sub>2</sub> production has been shown to be increased non-specifically in  $\gamma$ -linolenic acid fed mice *ex vivo*.

5 Cytokines are implicated in the pathogenesis of MS, with many studies showing an increase in myelinotoxic inflammatory cytokines (TNF- $\alpha$ , IL-1 $\beta$  and IFN- $\gamma$ ) coinciding with the relapse phase of the disease. TGF- $\beta$ 1 has been reported to protect in acute and relapsing EAE ((Racke et al (1993); Santambrogio et al (1993)), and PG inhibitors such as indomethacin augment, and thus worsen, the disease  
10 (Ovadia & Paterson (1982)).

Conversely, levels of the anti-inflammatory and immunosuppressive cytokine transforming growth factor-beta1 (TGF- $\beta$ 1) appear to be reduced during a phase of relapse and increase as the patient enters remission. Thus the balance between biologically active TGF- $\beta$ 1 and the pro-inflammatory TNF- $\alpha$ , IL-1 $\beta$  and IFN- $\gamma$   
15 appears to be dysregulated during MS relapse-remission.

During natural recovery phase from EAE, TGF- $\beta$ 1-secreting T-cells inhibit EAE effector cells, TGF- $\beta$ 1 is expressed in the CNS and, in oral-tolerance-induced protection in EAE, TGF- $\beta$  and PGE<sub>2</sub> are expressed in the brain (Karpus & Swanborg (1991); Khoury et al (1992)). Harbige ((1998) concluded that dietary  $\gamma$ -linolenic acid  
20 effects on EAE are mediated through Th<sub>3</sub>-like mechanisms involving TGF- $\beta$ 1 and possibly through superoxide dismutase antioxidant activity.

In spite of the use of Borage oil and other  $\gamma$ -linolenic acid/linoleic acid containing oils such as Evening Primrose oil by multiple sclerosis sufferers over the past 30 years or so, the vast majority of patients fail to recover from the disease,  
25 showing no significant improvement, with the underlying disease continuing to progress to death.

It has been suggested to use, *inter alia*,  $\gamma$ -linolenic acid and linoleic acid rich Borage oil as a means to provide immuno-suppression in multiple sclerosis (US 4,058,594). Critially, the dose suggested is 2.4 grams of oil per day and no actual  
30 evidence of efficacy is provided. This is much lower than the low 5gram/day dose that the present inventors have now found to be ineffective *in vivo* in man as reported in PCT/GB04/002089, indeed the inventors have found that doses as high as 10 gram/day have been found to be ineffective in some patients.

Other more dramatic immunosuppressant treatments, including T cell depleters and modulators such as cyclophosphamide, are also shown to be effective in the EAE model, but where these are employed in the human multiple sclerosis disease symptoms improve, but the underlying disease continues to progress. This is probably  
5 because T-cells indeed produce beneficial cytokines, such as TGF- $\beta$ 1, as well as deleterious ones in man.

David Baker of Institute of Neurology, UK summed up the disparity between what is effective in the EAE and in MS with a paper entitled '*Everything stops EAE, nothing stops MS*' at the 10<sup>th</sup> May 2004 UK MS Frontiers meeting of the UK MS  
10 Society. It is clear that immunosuppression alone cannot cure MS. This is almost certainly due to a fundamental underlying metabolic disorder in MS patients (Hollifield et al (2003) Autoimmunity, Vol 36, p133-141), in addition to the autoimmune disease, that leads to membrane abnormality, cytokine dysregulation and subsequent immune attack and lesioning. Although patients go into remission in  
15 relapse-remitting disease, the underlying demyelination proceeds.

The 'gold standard' treatment for MS remains interferon, such as with  $\beta$ -Avonex ®, Rebif ® and other interferon preparations. This gold standard treatment only addresses needs of some, eg 30%, of the patients and even in these symptom improvement is restricted to reduced severity of relapses. Whilst symptoms may be  
20 reduced in a proportion of patients, the disease tends to progress to further disability and death due to underlying degeneration.

The copending PCT/GB2004/002089 and PCT/GB2004/003524 show that administration of a suitably high level of  $\gamma$ -linolenic acid, dihomo- $\gamma$ -linolenic acid and/or arachidonic acid as lipid sn-2 position fatty acid residue, is capable of  
25 achieving the immunoregulation and metabolic defect correction that is required to successfully arrest the otherwise inevitable decline seen in multiple sclerosis patients.

However, the inventors are aware that it is desirable to achieve as much efficiency as possible when administering these fatty acids if a patient that is taking such doses long term is to be kept from entering a pro-inflammatory, and thus  
30 disease worsening state. Any  $\gamma$ -linolenic acid, dihomo- $\gamma$ -linolenic acid and arachidonic acid that does not enter the membrane can end up as free fatty acid overflowing into other pools, eg. resulting in Th-2 like humoral responses and increasing neutrophil mediated inflammation. To this end the inventors have now

developed their unpublished invention further by preparing and testing structured phospholipids that are still more efficacious at directing these key fatty acid to the cell membranes but not elsewhere.

Two pools of polyunsaturated fatty acids (PUFA) are thought to exist for  
5 eicosanoid (e.g. prostaglandin) biosynthesis: a metabolic pool and a membrane-bound pool. There is little doubt that free arachidonic acid is converted into prostoglandins but there is little, if any, free arachidonic acid available under "normal" conditions as most is bound up in phosphoglycerides. Basal prostaglandin synthesis obtains its fatty acid precursors from a metabolic pool which starts from  
10 linoleic acid (18:2n-6) and is consequently linked to dietary intake (linoleic acid is quantitatively the major PUFA found in the diet) and that are found in the neutral lipid pool e.g. triacylglycerols and free fatty acids.

The substrates for this metabolic pool would be derived from dietary fats and from their mobilization in adipose tissue. Normally the longer-chain highly  
15 unsaturated fatty acid derivatives (e.g.  $\gamma$ -linolenic acid, dihomo- $\gamma$ -linolenic acid and/or arachidonic acid) are at low levels in the normal diet and are differentially incorporated directly into phosphoglycerides (phospholipids pool). The phosphoglyceride (phospholipids) pool becomes active under conditions of trauma (e.g. inflammation) rather than the metabolic pathway. This is of course the classic  
20 phospholipase, free arachidonic acid, cyclooxygenase, lipoxxygenase pathway.

Thus when a patient is fed high levels of these three n-6 fatty acids, not normally seen the diet, there is optimal incorporation of these fatty acids into phosphoglycerides, but once that level has been reached there is "overload" and these biologically highly active species will spill into the metabolic pool and be oxidised  
25 e.g. to the highly vasoactive prostaglandins. The optimal incorporation may vary under different disease conditions

In consequence, for triglycerides, there can be only a limited amount of sn-1 and sn-3  $\gamma$ -linolenic acid, dihomo- $\gamma$ -linolenic acid and/or arachidonic acid that can be tolerated as once these are released by lipases in the gut or in the mucosal cell  
30 (enterocyte) they are "free". Although some re-esterification into triglyceride takes place in the mucosal cell, the bulk will enter the metabolic pool and alter the normal homeostatic processes, controlled by e.g. prostaglandins, such as vascular physiology.

It is known that atherogenic potential is associated with saturated and monounsaturated C20 to C24 fatty acids (particularly the very long chain C22 and their monenes), but not with C2-8, C10, C12, C14, C16 and C18 fatty acids. The latter are therefore preferred fatty acids for use in the structured lipids of the  
5 copending and present patent applications in positions where fatty acids will be lost to the metabolic pool.

The inventors have determined that the level of sn-1 linoleic acid may account for the lower potency of borage oil vs fungal oil shown in prior art EAE studies through competition and conversion to 20:2n-6 which will compete in membrane  
10 phospholipid sn-1 and sn-2 with  $\gamma$ -linolenic acid, dihomo- $\gamma$ -linolenic acid and/or arachidonic acid. A mucosal cell 1,2-diglyceride pathway exists that gives rise to glycerophospholipids which may also be important regards competition between linoleic acid and these acids and/or linoleic acid's effects on micelle solubility.

Fat digestion in the small intestine (duodenum) involves pancreatic lipase  
15 which hydrolyzes the sn-1 and sn-3 positions of triacylglycerols after these are emulsified with bile salts (triacylglycerols or triglycerides are the major fat in diet, with much smaller amounts of phospholipids being present). The products of this digestion are free fatty acids and sn-2 monoglycerides. Micellar formation solubilizes the monoglycerides and fatty acids. This process appears to be affected by the  
20 presence of phospholipids and monoglycerides, furthermore mixed micelles e.g. containing oleic and linoleic acid (monoolein and monolinolein) appear to be better absorbed and improve the absorption of other fatty acids.

Monoglycerides, dietary cholesterol and fatty acids from the micelles enter the mucosal cells by passive diffusion. Fatty acids of C10-12 carbon or less pass from the  
25 mucosal cells directly into the portal blood, where they are transported as free (unesterified) fatty acids to the liver. This is the basis for the clinical use of medium chain triglycerides (MCTs) in burns, surgery, trauma etc. Fatty acids containing more than 10-12 carbon atoms are re-esterified to triglycerides in the mucosal cells (see Fig 1). In the mucosal cells, most of the triglyceride is formed by the acylation of the  
30 absorbed 2-monoglycerides at the smooth endoplasmic reticulum. The new triglyceride, which retains sn-2  $\gamma$ -linolenic monoglycerides, is transported (after packaging with a protein [B48,CII,AI] component within the mucosal cell Golgi) in chylomicrons to the central lacteal of the villus and carried in the lymphatic system



(Fig 1). Lymph vessels course between the layers of the mesentery to the pre-aortic lymph glands and empty into the thoracic duct to the systemic circulation.

Circulating dietary triglycerides, as part of chylomicons, are transported to the liver and also removed from the blood, as they are in the lymphatics, by lipoprotein  
5 lipase on the luminal side of capillary beds in e.g. muscle, heart, adipose tissue. Lipoprotein lipase acts on the sn-1 and sn-3 fatty acids supplying e.g. adipocytes with fatty acids which then re-esterify the fatty acids into triglycerides (fat deposition). Release by adipose tissue surrounding lymph nodes (this adipose tissue preferentially incorporates PUFA) supplies the node with fatty acids for membrane synthesis  
10 (PUFA) and energy (saturates).

Thus dividing/proliferating lymphocytes (greatly increased under EAE, CREAE and other autoimmune conditions) incorporate fatty acids, allowing for triglyceride incorporation directly into lymphocyte membranes.  $\gamma$ -linolenic acid will require conversion to dihomo- $\gamma$ -linolenic acid and arachidonic acid and it is then there  
15 will be an impact on the cytokine production pattern of the T-lymphocytes, under activation conditions, to a localised T cell TGF- $\beta$ 1 (T regulatory cell) dominated response rather than a  $\gamma$ -IFN dominated T cell response (note these are the effector T cells that mediate EAE). PGE<sub>2</sub> production by regulatory macrophages/monocytes is also potentially important.

20 In contrast to the triglycerides of copending PCT/GB2004/003524, it appears that dietary phospholipids are acted on by a pancreatic phospholipase A2 in the intestine releasing the sn-2 fatty acid present (usually an unsaturated fatty acid such as linoleic or arachidonic acid) and forming a lysophosphatidyl moiety (sn-2 lyso-phospholipid). The unsaturated fatty acids released are absorbed as free fatty acids  
25 and reincorporated into glycerolipids which are made into new phospholipids (Fig 1) in the rough endoplasmic reticulum.

Thus during fat absorption chylomicron phospholipids are derived from reacylation of the absorbed sn-2 lysophosphatidyl compound (eg phosphotidylcholine), increased *de novo* synthesis and mucosal phospholipid pools. It  
30 is also thought that there is preferentially reacylation, although the specificity of the intestinal 1-lyso-PC-acyl-CoA-acyltransferase has not been fully studied, of  $\gamma$ -linolenic acid, dihomo- $\gamma$ -linolenic acid, arachidonic acid and to a lesser extent linoleic acid into the 1-lyso-PC (sn-1 of PC). Thus the theory is that the sn-1 in eg.

phosphatidylcholine, should remain relatively intact which would target the sn-1 fatty acid to the membrane pool.

It appears from the limited published data and the inventors own observations that the preferential transport of chylomicron phospholipids, combined with a positional specificity of lipoprotein lipase and hepatic and lymphoid tissue lipases for sn-1 of phospholipids such the phosphatidyl esters PC (phosphatidylcholine) and PE (phosphatidylethanolamine), is important. It provides a physiologically important transport system for high amounts of the biologically potent longer chain n-6 fatty acids which can be distributed to various organs/tissues without any risk of uncontrolled physiological effects caused by intravascular release of these fatty acids, particularly arachidonic acid, in their free unesterified form.

It is known that preferential incorporation of free arachidonic acid (orally dosed) into the chyle phospholipids occurs, but on giving high doses, arachidonic acid-rich triglycerides are also observed, indicating overflow into the triglyceride pool. It should be appreciated that chylomicrons transporting lipids e.g. phospholipid are providing lipids for the growth of body tissues/cells/membranes and can be directly incorporated into membranes.

In contrast the triglyceride fatty acids are stored in adipose tissue and released, in the case of lymphoid tissues to provide additional fatty acids, both saturated and unsaturated, for membrane incorporation in actively proliferating lymphocytes. It should be noted that lymphocytes preferentially use glutamine and fatty acids as their metabolic fuel rather than glucose; there maybe however direct triglyceride incorporation.

The present invention provides new phospholipids, particularly but not exclusively 3-sn-phosphatidyl esters, and identifies known phospholipids that will deliver  $\gamma$ -linolenic acid, dihomo- $\gamma$ -linolenic and arachidonic acid directly into the cell membrane with much reduced risk of free fatty acid release. Should  $\gamma$ -linolenic acid not undergo sufficient metabolic conversion by this route, perhaps due to individual patient idiosyncrasy, the preformed dihomo- $\gamma$ -linoleic acid or arachidonic acid phospholipids will be more active. In addition these enriched phospholipids have a potential role in membrane reparation, such as for neural membranes in multiple sclerosis, where underlying  $\delta$ -6 desaturase activity is now thought to be deficient.

It is known from EP0609078 and US5466841 to prepare phospholipids including two different unsaturated fatty acids selected from the twelve n-6 and n-3 essential fatty acids (EFA), oleic acid and combinic acid. The use of such phospholipids is said to be for administration of a single component molecule that can provide supplementation for dietary essential fatty acid insufficiency. The implication of this teaching is that two essential fatty acids may be supplemented in one molecule, with no preference being given to the position of the EFA at sn-1 or sn-2 the phosphotidyl group being at sn-3). These patents/applications teach preparation and use of phosphatidyl-serine, phosphatidyl-choline, phosphatidyl-ethanolamine and phosphatidyl-inositol derivatives of the EFAs.

US3577446 describes the synthesis of phosphatidylalkanolamines, particularly 1,2-di-(octadeca-9,12,15-trienoyl)-sn-glycero-3-phosphorylethanolamine useful as antihypertensive agents. This has two identical fatty acid residues attached to the sn-1 and sn-2 residues of a phosphatidylethanolamine group. JP 63-225387, JP 3-153628 and JP 61-129190 all describe phosphatidyl based infusions. EP0147741 describes 1,2-diacylglycero-3-phosphatidyl-cholines as additives in tablets at levels of 100mg per tablet.

In the present application the inventors describe the use of 1,2-diacyl-3-phosphatidyl esters of n-6 fatty acids for the treatment of diseases requiring modulation of dysregulated cytokines, these cytokines being particularly TGF- $\beta$ 1, but also cytokines TNF- $\alpha$  and IL-1 $\beta$ .

Diseases that are treated are particularly neurodegenerative conditions, particularly those such as demyelinating diseases, such as multiple sclerosis, Alzheimer's and Parkinsons diseases and the degenerative sequelae associated with head trauma, stroke and intracranial bleeds, whereby neuronal function may be improved or restored from an impaired condition, eg. by remyelination.

Particularly however the present invention relates to the treatment of multiple sclerosis, more preferably where the patient has deficits in TGF $\beta$ 1 release from PBMCs and/or a deficit in arachidonic acid levels in PBMCs. Most preferably the disease treated is relapse remitting MS, secondary progressive MS or primary progressive MS.

A key advantage of the present invention comes with the realisation that the position of the essential fatty acyl groups  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl and

arachidonoyl in a lipid has significance for its therapeutic efficacy, as set out in the aforesaid PCT application and theorised above. This may be particularly serious where free fatty acid release results in arachidonic acid overdose, but may also be produced with overdose of the precursors  $\gamma$ -linolenic acid and dihomo- $\gamma$ -linolenic acid. Paradoxically, previous treatment regimens using  $\gamma$ -linolenic acid rich oils, such as Evening Primrose Oil and lower sn-2 content Borage Oils, have provided too little sn-2-GLA to have any effect, as demonstrated by PCT/GB2004/002089's low dose (5g/day).

In a first aspect the present invention provides a method of treating a patient in need of therapy for a diseases in which cytokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterified with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl acid and arachidonoyl.

Preferably is provided a method for treating a patient in need of modulation of transforming growth factor  $\beta$  (TGF- $\beta$ ), particularly TGF- $\beta$ 1, but also cytokines TNF- $\alpha$  and IL-1 $\beta$ , still more preferably for maintaining and/or restoring cytokine balance where imbalance is found in diseases of the immune system and in neurodegeneration. Such diseases include multiple sclerosis and autoimmune disease states.

Particularly there is provided a method of treating a patient in need of therapy for a dysregulated or beneficially modulatable cytokine disease, particularly a neurodegenerative disease, comprising administering to that patient a therapeutically effective dose of a defined structure phospholipid comprising a phosphatidyl group esterified with one or more fatty acyl groups, characterised in that the lipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group selected from the group consisting of  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl acid and arachidonoyl.

More preferably the phospholipid has a fatty acyl group selected from the group consisting of  $\gamma$ -linolenoyl acid, dihomo- $\gamma$ -linolenoyl acid and arachidonoyl at only one of the sn-1 or sn-2 positions of the phosphatidyl group, the other position

being free hydroxyl or esterified with a C2 to C36 unsaturated, monounsaturated or polyunsaturated fatty acyl group.

Still more preferably the phospholipid has a an sn-1 position fatty acyl group selected from  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl and arachidonoyl and an sn-2  
5 position fatty acid selected from C2 to C36 unsaturated, monounsaturated or polyunsaturated fatty acyl other than n-6 acids.

Most preferably the other fatty acid is such that it is used in the metabolic pool, eg. being unsaturated or a metabolically acceptable acid such as oleic or palmitic acid.

10 The phospholipid phosphatidyl group is preferably selected from those found in mammalian, particularly human, cell membranes, more preferably is selected from the group consisting of phosphatidyl-choline, phosphatidyl-ethanolamine, phosphatidyl-serine, phosphatidyl- inositol, plasmalogens of the above e.g. lyso-phosphatidyl-choline, lyso-phosphatidyl-ethanolamine, lyso-phosphatidyl-inositol  
15 and lyso-phosphatidyl-glycerol.

Particularly advantageously treated neurodegenerative diseases are those involving demyelination. The present method specifically arrests underlying neurodegeneration and restores neuronal function. Particularly the method normalises membrane composition, in immune cells and neurones, and restores healthy PBMC  
20 spontaneously released TGF- $\beta$ 1/TNF $\alpha$  ratios and the ratios of TGF- $\beta$ 1 with other PBMC released cytokines.

Most advantageously the method arrests neurodegeneration in multiple sclerosis of all types but particularly relapsing remitting, primary and secondary progressive and other chronic progressive MS and the restoration, in part or  
25 completely, of neuronal function such as measured, eg. By MRI or CAT scan or by EDSS score. EDSS score preferably is improved by at least one point, more preferably at least 1.5 points and most preferably by at last 2 points over 18 months of daily treatment. Such method may also be used in treatment of cerebral impairment after stroke, head trauma and intracranial bleeding where there is infarct, eg.  
30 demyelination or neuronal damage. Further application is provided in treating other chronic demyelination such as in Alzheimer's and Parkinson's disease.

Preferably the the phospholipid is administered for a duration and at a dose sufficient to maintain or elevate TGF- $\beta$ 1 levels in the patient to therapeutic levels. By


therapeutic levels is meant levels at least consistent with healthy subjects. Preferably the dose is such as to produce a TGF- $\beta$ 1/TNF- $\alpha$  ratio spontaneously released from peripheral blood mononuclear cells (PBMCs) isolated from blood of a patient, after 18 months of daily dosing, of 0.4 to 3.0, at least 0.5, more preferably at least 0.75 and  
5 most preferably at least 1. Preferably the dose is such as to produce a TGF- $\beta$ 1/IL-1 $\beta$  ratio in blood of a patient, after 18 months of daily dosing, of at least 0.5, more preferably at least 0.75 and most preferably at least 1. Preferably said levels are produced after 12 months and more preferably after 6 months.

Examples of healthy TGF- $\beta$ 1 are 80pg/ml or more per  $2 \times 10^6$  cells  
10 spontaneously released from peripheral mononuclear blood cells isolated from the patient, more preferably above 100pg/ml and most preferably above 140pg/ml, still more preferably greater than 180pg/ml. Methods for measuring this release are described in the Examples section herein.

Typically the amount of phospholipid administered daily will be between 0.5  
15 and 30 grams, orally dosed, still more preferably between 0.5 and 20 grams and most preferably between 0.5 and 10 grams, typically 1 to 8 grams and most preferably between 1.2 and 3 grams.

Where the obligate (ie. the fatty acyl that is required to be present) sn-1 or sn-2 fatty acyl group is  $\gamma$ -linolenoyl, the dose may be toward the higher end of these  
20 ranges, particularly where the other sn-1 or sn-2 group is relatively inert, eg. being metabolically utilised acids such as saturated fatty acids. Where the obligate sn-1 or sn-2 fatty acyl group is dihomo- $\gamma$ -linolenoyl, the dose may be less, whilst where it is arachidonoyl, efficacy is higher, but dosing should be more cautious, due to possibilities of unwanted side effects at higher levels.

25 More preferably the method is characterised in that the phospholipid is a monoacyl or diacylphosphoglyceride, containing the at least one sn-1 or sn-2  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl or arachidonoyl group, of general Formula I below:



Formula I

wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from the group consisting of hydrogen,  
 5 γ-linolenoyl, dihomo-γ-linolenoyl and arachidonoyl, mono-unsaturated C<sub>3-36</sub>,  
 linoleoyl or n-3 polyunsaturated acyl groups and optionally substituted C<sub>2-36</sub> saturated  
 acyl, and

R<sup>3</sup> is selected from moieties that are conjugated to phosphatidyl groups  
 naturally occurring in mammalian membranes

10 with the condition that one of R<sup>1</sup> and R<sup>2</sup> must be selected from γ-linolenoyl, dihomo-  
 γ-linolenoyl and arachidonoyl.

For the purpose of the present invention the C<sub>2-36</sub> acyl groups comprise at least  
 one carbonyl group on the end of a hydrocarbonyl chain selected from alkyl and alkenyl  
 chains, the carbonyl group being directly attached by its carbon to the oxygen of the  
 15 glycerol residue shown in Formula 1

Preferred acyl groups R<sup>1</sup> and R<sup>2</sup>, when they are not γ-linolenoyl, dihomo-γ-  
 linolenoyl and arachidonoyl, are saturated acyl of formula -CO-(CH<sub>2</sub>)<sub>n</sub>-CH<sub>3</sub>, wherein  
 n is an integer selected from 1 to 22, more preferably being 4 to 16, still more  
 preferably being from 5 to 12, most preferably being from 6 to 10. Particularly  
 20 preferred acyl groups are those of caprylic and capric acids, particularly being 1,3-  
 dicaprylic or 1,3-dicapric glycerols having the γ-linolenoyl, dihomo-γ-linolenoyl or  
 arachidonoyl group at the sn-1 or sn-2 position, most preferably the sn-1 position.

Preferred groups R<sup>3</sup> are polar groups such as choline, ethanolamine, serine,  
 inositol and glycerol. Other naturally occurring groups R<sup>3</sup> will occur to those skilled  
 25 in the art in the light of these but may be tissue specific, eg. specific to T-cells or  
 nervous tissue. Other groups are preferably bipolar substituted C<sub>1-10</sub> alkyl or alkenyl

groups substituted with eg amine, hydroxy or thio at one end and hydroxyl at the other such that there is formed a phosphotidate ester with the polar group.

Whilst most preferred groups  $R^1$  to  $R^2$  for inclusion in the compound of formula I in addition to one of the three obligatory ('obligate') n-6 acyl groups, are  
5 simple saturated fatty acyl or naturally occurring fatty acyl with structural or metabolic function, such as medium chain or long chain fatty acyl, there are other possibilities. Particularly preferred fatty acyls are those that are utilised primarily by the metabolism for producing energy. Other preferred acyls for sn-1 and sn-2 are  
10 selected from fatty acyls that are metabolised in the human to yield energy as opposed to a fatty acid that is primarily directed to the structural membrane pool: such preferred acids include oleic acid and palmitic acid.

Where used herein residue with respect to the phospholipid, in respect of acyl, particularly fatty acyl, groups means the moiety that remains after the fatty acid carboxyl group esterifies to one of the hydroxy groups of the glycerol molecule.

15 Where the other, non-obligate, sn-1 and sn-2 fatty acid chain ( $R^1$  and  $R^2$ ) is unsaturated it may also be that of other essential fatty acids, such as the n-3 acids such as stearidonic acid, eicosapentanoic acid and docosahexanoic acid.

The non-obligate fatty acyl may be optionally substituted and these substitutions will preferably be by hydroxy, oxo, carboxyl, alkyl, alkenyl and alkoxy  
20 groups. Many naturally occurring substituted fatty acyls exist, eg. such as (R)-3-hydroxybutyrate and acetoacetate.

In a second aspect of the present invention there is provided the use of a compound of formula I, as defined above and with preferences of the method, for the manufacture of a medicament for the treatment of the diseases of the method of  
25 treatment.

In a third aspect of the invention there is provided a pharmaceutical composition for the treatment of a patient in need for modulation of dysregulated cytokines or cytokines which are otherwise capable of modulation to provide therapeutic benefit characterised in that it comprises a phospholipid comprising a  
30 phosphatidyl group esterified with one or more fatty acyl groups, characterised in that the lipid has a fatty acyl at the sn-1 and/or sn-2 position of the phosphatidyl group selected from the group consisting of  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl acid and arachidonoyl. Preferences are as for the method above.




Preferred compositions are for treating neurodegenerative conditions, particularly those such as demyelinating diseases, such as multiple sclerosis, Alzheimer's and Parkinsons diseases and the degenerative sequelae associated with head trauma, stroke and intracranial bleeds, whereby neuronal function may be improved or restored from an impaired condition, eg. by remyelination.

Compositions may comprise the pure phospholipid, but it is found that some of these are not stable over periods of weeks and months, at room temperature, in which case they can be stabilised by cold storage or by admixture with a diluent or carrier material. Suitable diluents and carriers can be found in the literature in texts such as Remington's Pharmaceutical Sciences. One particular material investigated by the inventors has been PEG (polyethylene glycol) eg. PEG200. This can be used at amounts between 1 and 99% PEG to 99% to 1% by weight of active phospholipid, preferably 20 to 80% PEG to 80 to 20% of phospholipid and more preferably 40 to 60% PEG to 60 to 40% by weight of phospholipid.

It will be realised by those skilled in the art that other beneficial agents may be combined with the lipids for use in the present invention or otherwise form part of a treatment regime with the lipids. These might be ion channel blockers, eg. sodium channel blockers, interferons ( $\alpha$ ,  $\beta$ , or  $\gamma$ ), T-cell depleters, steroids or other palliative agents. It will further be realised that where the immune and inflammatory responses are being modulated, such combinations will need to be made carefully, given the complex nature of these systems. However, given the delayed response to the present oils, shorter acting agents might be beneficial in the first months of treatment before the TGF- $\beta$ 1 levels are normalised, as long as the additional treatment does not impede this normalization process.

In a fourth aspect of the present invention there are provided novel phospholipids selected from monoacyl or diacyphosphatidyl compounds of general formula 1 containing at least one  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl or arachidonoyl group



Formula I

wherein  $\text{R}^1$  and  $\text{R}^2$  are independently selected from the group consisting of hydrogen,  
 5  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl and arachidonoyl,  $\text{C}_{3-36}$  mono-unsaturated fatty  
 acyl, linoleoyl or n-3 polyunsaturated acyl groups and optionally substituted  $\text{C}_{2-36}$   
 saturated acyl, and

$\text{R}^3$  is selected from moieties that are found conjugated to phosphatidyl groups  
 in mammalian cell membranes  
 10 with the condition that ONLY one of  $\text{R}^1$  and  $\text{R}^2$  MUST be selected from  $\gamma$ -linolenoyl,  
 dihomo- $\gamma$ -linolenoyl acid and arachidonoyl and the other is not one of these fatty acyl  
 groups.

For the purpose of the present invention the fatty acyl groups  $\text{R}^1$  and  $\text{R}^2$   
 comprise at least one carbonyl group on the end of a hydrocarbyl chain selected from  
 15 alkyl and alkenyl chains, the carbonyl group being directly attached by its carbon to  
 the oxygen of the glycerol residue shown in Formula 1

Preferred acyl groups  $\text{R}^1$  and  $\text{R}^2$ , when they are not  $\gamma$ -linolenoyl, dihomo- $\gamma$ -  
 linolenoyl and arachidonoyl, are saturated acid moieties, preferably fatty acyl, of  
 formula  $-\text{CO}-(\text{CH}_2)_n-\text{CH}_3$ , wherein n is an integer selected from 1 to 22, more  
 20 preferably being 4 to 16, still more preferably being from 5 to 12, most preferably  
 being from 6 to 10. Particularly preferred acyl groups are those of caprylic and capric  
 acids, particularly being 1,3-dicaprylic or 1,3-dicapric glycerols having the  $\gamma$ -linolenic  
 acid, dihomo- $\gamma$ -linolenic acid or arachidonic acid moiety at the sn-1 or sn-2 position,  
 most preferably the sn-1 position.

25 Preferred groups  $\text{R}^3$  include choline, ethanolamine, serine, inositol and  
 glycerol as described from the method. Other naturally occurring groups  $\text{R}^3$  will occur

to those skilled in the art in the light of these but may be tissue specific, eg. found in T-cells or nervous tissue, eg. neurons.

Similarly, other preferred acids for sn-1 and sn-2 are selected from fatty acids that are metabolised in the human to yield energy as opposed to a fatty acid that is primarily directed to the structural membrane pool: such preferred acids include  
5 palmitic acid.

The fatty acyl groups may be optionally substituted and these substitutions preferably are by hydroxy, oxo, carboxyl, alkyl, alkenyl and alkoxy groups.

A sixth aspect of the present invention provides method of synthesis of the  
10 novel and known compounds of the invention as set out herein in the schemes below.

Several of the compounds for use in the method of the present invention are known and can be produced by methods as set out in the attached references which are incorporated herein by reference. G indicates  $\gamma$ -linolenic acid, O indicates Oleic acid,  
15 A indicates arachidonic acid, DHLA indicates dihomogamma-linolenic acid, DOCO is docosohexanoic acid, and C is decanoyl (saturated) residue in each case. S is serine and Ln is linoleic and P is palmitoyl.

GGPc<sup>1,2</sup>, GOPc<sup>2</sup>, AAPc<sup>3,4</sup>, DHLA(DHLA)Pc<sup>5,6</sup>, DOCO(DOCO)Pc<sup>4,7</sup>, OOPc<sup>8</sup> and CCPc<sup>9</sup> are all known compounds. However, GCPc and CGPc are  
20 believed novel. Chemie Linz<sup>10</sup> which describes POPc, SOPc, SLPc, and SAPc. PAPc<sup>11</sup> and SLPc<sup>12</sup> have also been prepared.

A preferred exemplary known phospholipid for use in the method, composition and use of the invention *1,2-Di( $\gamma$ -linolenyl)-sn-glycerophosphocholine*  
25 GGPc

The invention provides a first method of its preparation of compounds GGPc, DHGLADHGLAPc and AAPc in a one step process (scheme 5, method A) by reaction of sn-glycerophosphocholine cadmium complex with  $\gamma$ -linolenic, dihomogamma-linolenic, or arachidonic anhydride (formed eg. from the n-6 acid and  
30 dicyclohexylcarbodiimide). Purification of the crude product uses eg. copper sulfate washes to remove DMAP and column chromatography to take out other by-products. The first batch of product for the  $\gamma$ -linolenic product (44 g, 85% purity) was obtained

as a yellow wax. Over 6 months this material was found to have deteriorated to only 70% purity and was now a brown colour suggesting oxidation had occurred.

On a 7 g scale higher purity GGPc could be obtained by more rigorous chromatography. Furthermore freeze-drying a dioxan solution of this material gave a white solid. This solid was hygroscopic and gained weight and went to a foam on prolonged exposure to the atmosphere.

An improved procedure (scheme 5, method B) was used which reacted sn-glycerophosphocholine cadmium complex with  $\gamma$ -linolenic (or other n-6 acid) imidazolid (from eg. GLA and carbonyldiimidazole) in the presence of dimethyl sodium in DMSO. This reaction is much faster and cleaner since there is less contamination by reactant by-products and excess reagents. Purification by chromatography and freeze-drying is still preferable but is much easier in this case. The batch of GGP obtained was a tan sticky solid (93% purity: the starting GLA is 95% pure (Scotia) and two GLA residues are incorporated into the phospholipid). This was stored at  $-20^{\circ}\text{C}$  under nitrogen. The white solid can be obtained by freeze-drying concentrated dioxan solutions..

A process for providing the preferred novel phospholipids of the invention such as GCPc (5) includes a 4 step route shown in scheme 4 which also uses sn-glycerophosphocholine cadmium chloride complex as starting material. The first stage intermediate, 1-trityl-sn-glycerophosphocholine (TritylPc, 2), is known<sup>10,13</sup> and was prepared it by carrying out the literature procedure on a larger scale and in a modified manner.

The second step intermediate TritylCPc (3) and the products GCPc, DHGLACPc and ACPc are novel. Synthesis involves the acylation at the 2-position of the tritylglycerophosphocholine (TritylPc, 2). Reaction of the latter with either the saturated fatty acyl chloride or anhydride, eg decanoyl chloride or decanoyl anhydride (from decanoic acid and DCC) in chlorinated solvents gives low yields of the desired product. When the sodium salt of TritylPc was formed in DMSO by reaction of TritylPc with dimethyl sodium it underwent rapid acylation with decanoyl imidazolid (from decanoic acid and carbonyl diimidazole) to give TritylCPc (3).

The third and fourth steps consist of deprotection of the trityl group of TritylCPc using  $\text{BF}_3$  etherate followed by acylation at the 1-hydroxyl group of

intermediate 4 with  $\gamma$ -linolenoyl anhydride to yield GCPc (5). Use of the anhydride corresponding dihomio or arachidonyl anhydride accesses the corresponding final products. However, initial attempts focused on the 'two steps in one pot strategy' which had been reported to work<sup>13</sup> to give phosphocholines such as POPc uncontaminated with OPPc (by migration of the 2-acyl group to the 1-position in the deprotected intermediate). When it was tried to apply this methodology to GCPc first was only obtained the deprotected intermediate 4. Eventually a very low yield of GCPc (2%).

To circumvent these problems steps 3 and 4 are preferably carried out separately. Deprotection may be effected by acetic acid at 55 °C; acylation by  $\gamma$ -linolenoyl (or corresponding other n-6 acid) anhydride catalysed by DMAP. These reactions give better yields on a small-scale.

The route that has been provided to prepare CGPC 5 and its corresponding dihomio and arachidoyl compounds is shown in scheme 1. It starts from glycerophosphocholine cadmium chloride complex 1 and uses trityl protected intermediates 2 and 3 to control the regiochemistry of the fatty acid chains at the sn-1 and sn-2 positions. The most problematical step is the deprotection. The key to success lies in the ability to monitor reactions because of the UV-absorbing properties of the GLA unit. Deprotecting agents such as dilute hydrochloric acid in dioxan at 80 °C or formic acid in ether at room temp appear to have worked well.

A second, one-stage more direct route (scheme 2) is provided which involves the sequential acylation of glycerophosphocholine with unsaturated fatty acyl, eg decanoyl, imidazolide and then GLA, dihomio-GLA or arachidonyl-imidazolide. Although mixtures (and hence substantial purification) may be expected the problems associated with protecting groups are avoided.

GCPc (8) (or corresponding dihomio or arachidonyl compound) may be prepared by the 4 step route shown in scheme 3 which also uses sn-glycerophosphocholine cadmium chloride complex 1 as starting material and trityl protected intermediates. The route is similar to that in scheme 1 for CGPC but the fatty acids are introduced in reverse order.

## References

1. T. Rezanka and M. Podojil, *J. Chromatogr. A*, **463**, 397-408 (1989)  
Preparative separation of algal polar lipids and of individual molecular species by  
high-performance liquid chromatography and their identification by gas  
5 chromatography-mass spectrometry.
2. D. Horrobin, A. Mc|Mordie and M. S. Manku, Eur. Pat. Appl. EP 609078 A1  
3 Aug 1994 (Scotia Holdings PLC). Phospholipids containing two different  
unsaturated fatty acids for use in  
10 therapy, nutrition and cosmetics.
3. F. H. Chilton and R. C. Murphy, *Biophys. & Biochem. Res. Comm.*, **145**,  
1126-1133 (1987).
- 15 4. C. J. Dekker, W. S. M. Geurts van Kessel, J. P. G. Klomp, J. Pieters and B.  
De Kruijff, *Chem. Phys. Lipids*, **33**, 93-106 (1983).
5. C. S. Ramesha and W. C. Pickett, *J. Lipid Res.*, **28**, 326-331 (1987)
- 20 6. E. L. Pugh and M. Kates, *J. Biol. Chem.*, **252**, 68-73 (1977)
7. N. Fukuda, H. Nobuo and O. Nakachi, Japanese Patent JP 01141598 A2 2  
Jun 1989 (Nippon Oils & Fats Co.)
- 25 8. T. G. Warner and A. A. Benson, *J. Lipid Res.*, **18**, 548-551 (1977)
9. A. J. Slotboom, R. Verger, H. M. Verheij, P. H. M. Baartmans, L. L. M. Van  
Deenen and G. H. De Haas, *Chem. Phys. Lipids*, **17**, 128-147 (1976).
- 30 10. F. Paltauf and A. Hermetter, US Patent 4,622,180 11-11-1986 (Chemie Linz  
AG Derivatives of glycerophosphocholine and glycerophosphoethanolamine,  
their preparation and their use
11. Jie Xia and Yong-Zheng, *Chem. Pharm. Bull.*, **47**, 1659-1663 (1999)

12. Jie Xia and Yong-Zheng, *Bioorg. Med. Chem. Lett.*, 5, 1919-1922, (1995)
13. G. Borsotti, G. Guglielmetti, S. Spera and E. Battistel, *Tetrahedron*, 57, 10219-10227 (2001). Synthesis of Phosphatidylcholines containing Ricinoleic acid.

5 The present invention will now be described by way of illustration only by reference to the following non-limiting synthesis and biology Examples, Tables and Figures. Further embodiments falling within the scope of the claims will occur to those skilled in the art in the light of these.

## 10 FIGURES

Figure 1: Shows the synthetic route for synthesis of CGPc.

Figure 2: Shows the synthetic route for synthesis of CGPc.

15

Figure 3: Shows a synthetic route for synthesis of GCPc.

Figure 4: Shows a synthetic route for synthesis of GCPc.

20 Figure 5: Shows the synthetic route for synthesis of GGPc.

## NMR.

Proton-decoupled  $^{13}\text{C}$  NMR spectra with suppressed NOE were collected at 21 °C in a 5-mm broadband probe on a Joel 500 MHz spectrometer operating at 125.728 MHz.

25 Waltz decoupling was the chosen mode of decoupling and was gated on only during the 14.89s acquisition time. The relaxation delay was set at 30 secs and the pulse angle was 90°. The spectral window used was ca.35 ppm (from 173.5 to 172.6 ppm) with a 170 ppm offset. The spectra were internally referenced to  $\text{CDCl}_3$  at 77.0 ppm. Typically, the approximate number of scans collected for adequate signal-to-noise

30 ranged from 300 to 1200 scans depending on the concentration and purity of the sample. The total acquisition time for the experiments ranged between 2-8h e.g 1272 scans; data points 65,536. Concentrated solutions up to 20% w/v were employed when possible to reduce the acquisition time. The chemical shifts quoted vary with the concentration of the solution.

**EXAMPLE 1****Example 1a****1,2-Di( $\gamma$ -linolenyl)-sn-glycerophosphocholine GGPC****5 Method A**

To a solution of  $\gamma$ -linolenic acid (138 g, 0.5 mol, 4 equiv) in DCM (750 ml) was added dicyclohexylcarbodiimide (56.4 g, 0.275 mol, 2.5 equiv) and the reaction mixture was stirred under a nitrogen atmosphere for 3 h at room temperature.

To the resulting mixture was added sn-glycerophosphocholine.CdCl<sub>2</sub> complex  
10 (55 g, 0.124 mol, 1 equiv; previously dried overnight in a vacuum oven at 75 °C over P<sub>2</sub>O<sub>5</sub>), followed by DMAP (30.3 g, 0.248 mol, 2 equiv). The reaction mixture was stirred for 72 h in the dark at room temperature, then filtered (Celite), the filter pad washed with DCM (200 ml) and the combined filtrate and washings washed with copper sulfate solution (2 x 300 ml) [to remove DMAP]. After drying over MgSO<sub>4</sub>  
15 the solvent was removed in vacuo. Ethanol and toluene were added to aid complete removal of water. The residual foam was chromatographed on silica (500g), eluting with DCM-MeOH and gradually increasing the proportion of methanol from 0 → 60%. Combination and concentration of appropriate fractions afforded product (55 g) as a tan wax. HPLC purity 85.1%.  $\delta_C$  (125.7 MHz, CDCl<sub>3</sub>) 172.99 (1C, sn-2  
20 carbonyl), 173.21 (1C, sn-1, 3 carbonyls).

**Example 1 b****1,2-Di( $\gamma$ -linolenyl)-sn-glycerophosphocholine GGPC****Method B**

25 1,1'-Carbonyldiimidazole (CDI, 52.0 g, 0.32 mol, 3.2 equiv) was added in portions to a solution of  $\gamma$ -linolenic acid (83.4 g, 0.30 mol, 3 equiv) in dry THF (500 ml) and the mixture stirred at room temperature for 1h under nitrogen. The solvent was removed in vacuum. The sn-glycero-3-phosphocholine.CdCl<sub>2</sub> complex (1, 44.0 g, 0.10 mol, 1equiv; previously dried overnight in a vacuum oven at 75 °C over P<sub>2</sub>O<sub>5</sub>)  
30 was added to the residue and dissolved in dry DMSO (800 ml). A freshly prepared solution of dimethyl sodium [from Na metal (11.5g, 0.50 g, 5 equiv) in 500 ml DMSO] was then added at such a rate that the temperature stayed below 50 °C. The addition takes ca. 0.5h. The reaction mixture darkened, was stirred for 30 min and



then poured onto aqueous acetic acid (3L water-100 ml acetic acid). A sticky solid was collected by filtration and washed with water (1L). This material was dissolved in toluene (1.5 L) the solution washed with water (1L) and both layers filtered through glass fibre filters (to remove cadmium residues). The filtrate was warmed to 70 °C ( to break up the emulsion) , the toluene layer separated and the solvent removed in vacuo to give a dark viscous oil (150 g). This material was chromatographed on silica ( 1 Kg). Elution with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (30:70) and then methanol gave a tan syrup. The methanol fractions were analysed by HPLC and those of purity >93% combined. The impure fractions were re-chromatographed to give further product.

The above procedure was repeated on the same scale and the products combined. This material was freeze-dried from dioxan (1.5 L) to give a 70 g of a tan sticky solid (HPLC purity 93% ).

## 15 EXAMPLE 2

Experimental (Scheme 1)

CGPc 1-Decanoyl-2-γ-linolenoyl-sn-glycero-3-phosphocholine (5)

Stage 1. 1-O-Triphenylmethyl-sn-glycero-3-phosphocholine (2)

sn-Glycero-3-phosphocholine cadmium complex (1, 50.0 g, 0.11 mol, dried in a vacuum oven at 70 °C) and triphenylmethyl chloride (trityl chloride, 46.0 g, 0.16mol) were dissolved in dry dimethylformamide (400 ml) at 70 °C. Triethylamine (23 ml, 19.9 g, 0.19 mol) was then added and the mixture stirred for 0.5h at 70 °C with exclusion of moisture. When the reaction mixture had cooled powdered NaHCO<sub>3</sub> (50g, 0.6 mol) was added and the mixture stirred for 20 min at room temperature. Inorganic salts were removed by filtration and the filtrate poured onto diethyl ether (1 L) . The mixture was shaken and the ether decanted off. The residue was shaken with ether (2 x 150 ml), the ether decanted off, and the remaining oily material dissolved in dichloromethane (500 ml). Isobutanol (250 ml) was added, the resulting solution washed with 4% aqueous NH<sub>3</sub> solution and then filtered through celite. The organic layer was washed with water, dried over MgSO<sub>4</sub> , and stood overnight at 4 °C. A pale yellow solid deposited. This material was removed by filtration, washed with ether and dried in vacuo to give 20.2 g (36%) of the product (99% purity by HPLC)

Stage 2 1-Triphenylmethyl-2- $\gamma$ -linolenoyl-sn-glycero-3-phosphocholine (3)

1,1'-Carbonyldiimidazole (CDI, 16.4g, 0.10 mol, 2.2 equiv) was added in portions to a solution of  $\gamma$ -linolenic acid (GLA, 23.3 g, 0.084 mol, 1.9 equiv) in dry THF (325 ml) and the mixture stirred at room temperature for 2h under nitrogen. The solvent  
 5 was removed in vacuo to give a semi-solid residue. A solution of 1-O-triphenylmethyl-sn-glycero-3-phosphocholine (2, 22.0 g, 0.045 mol, 1equiv) in dry DMSO (125 ml) was then added to this residue followed by a freshly prepared solution of dimethyl sodium [from Na metal 2.93g (0.13 g, 2.8 equiv) in 220 ml DMSO at 60 °C for 0.5h]. The reaction mixture turned to a gel almost immediately,  
 10 was shaken and stirred for 30 min and then poured onto aqueous acetic acid (1.2 L of 0.1N). The oily mixture was extracted 2 x with dichloromethane-methanol (2:1), the combined extracts washed 2 x with methanol-water (1:1) to remove DMSO, and then dried over MgSO<sub>4</sub>. Removal of the solvent in vacuo gave a tan oil (43g. ). This material was chromatographed on silica (500 g). Elution with dichloromethane and  
 15 then CH<sub>2</sub>Cl<sub>2</sub>-MeOH-NH<sub>3</sub> soln (75:25:2) gave a yellow by-product. Further elution with MeOH-NH<sub>3</sub> soln (98:2) gave the product (19.9 g) as a white waxy solid of low mp (HPLC purity 95.7% )

Stage 3 2- $\gamma$ -linolenoyl-sn-glycero-3-phosphocholine (4)

20 Formic acid (60 ml, 1.6 mol) was added to a solution of 1-O-triphenylmethyl-2- $\gamma$ -linolenoyl sn-glycero-3-phosphocholine (3, 4.55 g, 0.01 mol) in diethyl ether (40 ml). The mixture was stirred at room temperature for 1h under N<sub>2</sub> and then concentrated in vacuo. The residue was dissolved in ether and again concentrated in vacuo to remove more formic acid. The residual syrup was triturated in hexane, and the hexane layer  
 25 decanted; the process was then repeated with hexane-ether (1:1, 2 x) and then ether (2 x). The remaining gum was chromatographed on silica. Elution with dichloromethane-methanol mixtures (100:0 to 0:100) and then 2% NH<sub>3</sub> solution in methanol gave 2.2 g of the product as a colourless glass HPLC purity 96.9%

$\delta_H$  (500 MHz, CDCl<sub>3</sub>) 0.89 (3H, t,  $J$  = 6.7 Hz, C-CH<sub>3</sub>), 1.24-1.41(8H, m, 4 x  
 30 CH<sub>2</sub>), 1.61(2H, m, CH<sub>2</sub>-C-C=O), 2.06 (4H, m, 2 x CH<sub>2</sub>-C=C), 2.32 (2H, t,  $J$  = 7.5 Hz, CH<sub>2</sub>C=O), 2.80 (4H, m, 2 x C=CH<sub>2</sub>C=C), 3.33 (9H, s, NMe<sub>3</sub>), 3.69 (2H, m, CH<sub>2</sub>N), 3.78-3.89 (2H, m, glycerol sn-1 OCH<sub>2</sub>), 3.9-4.0 (1H, m, glycerol sn-3 OCH<sub>2</sub>), 4.08 (1H, m, glycerol sn-3 OCH<sub>2</sub>), 4.28-4.38 (3H, m, POCH<sub>2</sub> + glycerol

sn-2 OCH), 5.28 (6H, m, olefinic H).

#### Stage 4 1-Decanoyl-2- $\gamma$ -linolenoyl-sn-glycero-3-phosphocholine (5)

5 Dicyclohexylcarbodiimide (12.7 g, 62 mmol, 10.5 equiv) was added to a solution of decanoic acid (20.2 g, 0.12 mol, 20 equiv) in dry dichloromethane (80 ml) under N<sub>2</sub>. The mixture was stirred for 1h and the precipitated dicyclohexylurea (DCU) removed by filtration. The filtrate, a solution of decanoic anhydride in dichloromethane, was added to a stirred solution of 2- $\gamma$ -linolenoyl-sn-glycero-3-phosphocholine (4, 3.04 g,  
10 5.9 mmol, 1 equiv.) in dichloromethane (40 ml). 4-Dimethylaminopyridine (0.72 g, 5.9 mmol) was then added and the mixture stirred for 3h. The mixture was filtered to remove DCU and the filtrate concentrated in vacuo. The oily residue (25 g) was chromatographed on silica. Elution with dichloromethane-methanol mixtures (100:0 to 0:100) and then methanol-ammonia solution (98:2) gave 2.0 g of the product as a  
15 colourless glass (HPLC purity 92.1%). A sample was freeze-dried from dioxan to give a waxy solid (HPLC purity 97.5%).

$\delta_H$  (500 MHz, CDCl<sub>3</sub>) 0.89 (6H, 2 x t,  $J = 6.7$  Hz, 2 x C-CH<sub>3</sub>), 1.24-1.43 (20H, m, 10 x CH<sub>2</sub>), 1.53-1.65 (4H, m, 2 x CH<sub>2</sub>-C-C=O), 2.07 (4H, m, 2 x CH<sub>2</sub>-C=C), 2.30 (2H, m, 2 x CH<sub>2</sub>C=O), 2.80 (4H, m, 2 x C=CH<sub>2</sub>C=C), 3.35 (9H, s, NMe<sub>3</sub>), 3.82  
20 (2H, m, CH<sub>2</sub>N), 3.95 (2H, m, glycerol sn-3 OCH<sub>2</sub>), 4.12 1H, m, sn-1 OCHH), 4.3-4.5 (3H, m, POCH<sub>2</sub> + glycerol sn-1 OCHH), 5.20 (1H, m, glycerol sn-2 OCH), 5.26-5.44 (6H, m, olefinic H).

#### 25 EXAMPLE 4

Scheme

2

GCPc 1- $\gamma$ -linolenoyl-2-decanoyl-sn-glycero-3-phosphocholine (8)

Stage 1. 1-O-Triphenylmethyl-sn-glycero-3-phosphocholine (2) as above

Stage 2 1-Triphenylmethyl-2-decanoyl-sn-glycero-3-phosphocholine (6)

30 1,1'-Carbonyldiimidazole (CDI, 13.0g, 0.080 mol, 2.3 equiv) was added in portions to a solution of decanoic acid (11.5 g, 0.0067 mol, 1.9 equiv) in dry THF (250 ml) and the mixture stirred at room temperature for 2h under nitrogen. The solvent was removed in vacuo to give a semi-solid residue. A solution of 1-O-triphenylmethyl-sn-

glycero-3-phosphocholine (2, 17.5 g, 0.035 mol, 1equiv) in dry DMSO (85 ml) was then added to this residue followed by a freshly prepared solution of dimethyl sodium [from Na metal 2.36g (0.12 g, 3 equiv) in 175 ml DMSO at 60 °C for 0.5h]. The reaction mixture turned to a gel almost immediately, was shaken and stirred for 30 min and then poured onto aqueous acetic acid (1 L of 0.1N). The oily mixture was extracted 2 x with dichloromethane-methanol (2:1), the combined extracts washed 2 x with methanol-water (1:1) to remove DMSO, and then dried over MgSO<sub>4</sub>. Removal of the solvent in vacuo gave a viscous oil which was dissolved in ether (50 ml). The ether solution was washed with 2 x 5% aqueous NaCl, treated with decolourising charcoal and dried over MgSO<sub>4</sub>. The solvent was removed in vacuo, stirred with dichloromethane (30 ml) for 5 min, the insoluble material (no UV absorption) removed by filtration and the filtrate concentrated in vacuo to a gum (19 g). This material was chromatographed on silica (250 g). Elution with dichloromethane and then CH<sub>2</sub>Cl<sub>2</sub>-MeOH-NH<sub>3</sub>soln (70:30:2) gave a yellow by-product. Further elution with CH<sub>2</sub>Cl<sub>2</sub>-MeOH-NH<sub>3</sub>soln (50:50:2) gave the product (14.1 g) as a white solid of low mp (HPLC purity 98% )  $\delta_H$  (500 MHz, CDCl<sub>3</sub>) 0.93 (3H, t, *J* = 7.0 Hz, C-CH<sub>3</sub>), 1.29 (12H, m, 6 x CH<sub>2</sub>), 1.67(2H, m, CH<sub>2</sub>-C-C=O), 2.40 (3H, t, *J* = 7.5 Hz, CH<sub>2</sub>C=O), 3.22 (9H, s, NMe<sub>3</sub>), 3.29 (2H, m, CH<sub>2</sub>N), 3.63 (2H,m, OCH<sub>2</sub>), 3.99 (2H, m, OCH<sub>2</sub>), 4.17 (4H, m, OCH<sub>2</sub> + H<sub>2</sub>O), 5.29 (1H, m, OCH), 7.30 and 7.45 (15H, m, aromatics).

### Stage 3 2-Decanoyl-sn-glycero-3-phosphocholine (7)

Formic acid (160 ml, 1.6 mol) was added to a solution of 1-O-triphenylmethyl-2-decanoyl-sn-glycero-3-phosphocholine (6, 8.5 g, 0.01 mol) in diethyl ether (80 ml). The mixture was stirred at room temperature for 1h under N<sub>2</sub> and then concentrated in vacuo. The residue was dissolved in ether and again concentrated in vacuo to remove more formic acid. The residual syrup was triturated in hexane, and the hexane layer decanted; the process was then repeated with hexane-ether (1:1, 2 x) and then with ether (4 x). The remaining gum was freeze-dried from dioxan to give 4.2 g of the product as a waxy solid.

### Stage 4 2-Decanoyl-1- $\gamma$ -linolenoyl-sn-glycero-3-phosphocholine (8)

Dicyclohexylcarbodiimide (12.7 g, 62 mmol, 10.5 equiv ) was added to a solution of  $\gamma$ -linolenic acid (GLA, 33.4g, 0.12 mol, 20 equiv) in dry dichloromethane (80 ml) under N<sub>2</sub>. The mixture was stirred for 1h and the precipitated dicyclohexylurea (DCU) removed by filtration. The filtrate, a solution of decanoic anhydride in dichloromethane, was added to a stirred solution of 2- $\gamma$ -linolenoyl-sn-glycero-3-phosphocholine (7, 3.04 g, 5.9 mmol, 1 equiv.) in dichloromethane (40 ml). 4-Dimethylaminopyridine (0.72 g, 5.9 mmol, 1 equiv) was then added and the mixture stirred for 3h. The mixture was filtered to remove DCU and the filtrate concentrated in vacuo. The oily residue (25 g) was chromatographed on silica. Elution with dichloromethane –methanol mixtures (100:0 to 0:100) and then methanol –ammonia solution (98:2) gave 2.0 g of the product as a colourless glass (HPLC purity 92.1%). A sample was freeze-dried from dioxan to give a waxy solid (HPLC purity 96.4%).

### **BIOLOGICAL STUDIES.**

#### **15 Chronic Relapsing Experimental Autoimmune Encephalomyelitis (CREAE) Studies .**

##### **Induction and Clinical Assessment of EAE**

CREAE was induced in C57B1/6 and SJL mice. Animals were injected subcutaneously with 100  $\mu$ g of the neuroantigen peptide MOG 35-55 (amino acid sequence MEVGWYRSPFSRVVHLYRNGK Genemed Synthesis, Inc) or 1 mg of mouse spinal cord homogenate (SCH), in phosphate buffered saline (PBS), emulsified by sonication for 10 min at room temperature, in incomplete Freund's adjuvant (DIFCO, Detroit, USA) supplemented with 480  $\mu$ g of *mycobacteria tuberculosis* and 60 $\mu$ g of *Mycobacteria butyricium* (DIFCO, Detroit, USA) on days 0 and 7 as described previously (Morris-Downes, MM., et al 2002). In addition to optimise the disease mice also received 200 ng (intraperitoneally) of *Bordetella pertussis* toxin dissolved in PBS administered 1hr and 24 hrs after immunization with the MOG neuroantigen and for SCH days 0, 1, 7 and 8.

Animals were weighed from day 5 onwards and examined daily for clinical neurological signs by two experienced investigators and graded according to a previously validated grading scheme (Morris-Downes, MM. et al 2002 and others): 0 = normal; 1 = limp tail and feet; 2 = impaired righting reflex; 3 = partial hind limb paralysis; 4 = complete hindlimb paralysis; 5 = moribund; 6 = death. Animals

exhibiting clinical signs of a lesser severity grade than typically observed were scored as 0.5 less than the indicated grade.

### Reference

- 5 Morris-Downes, MM., et al (2002). Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice. *J. Neuroimmunol.* 125. 114-124.

The mean group EAE score was compared for each test group compared to a respective control group by non-parametric statistical analysis (Mann Whitney U  
10 Test).

All MOG-CREAE studies comprised a treatment control group (**saline**). Each structured phospholipid was tested at 3 dose levels, all treatments being orally administered for 2 weeks from day 7 after inoculation. All treatment groups will contained 10 animals. On completion of studies (day 21), brain and spinal cord were  
15 be removed and half of the samples were processed for signs of CNS perivascular mononuclear leucocyte-infiltrated sites and demyelination.

### RESULTS

20 Initial results confirm that GGPc was superior in efficacy in the CREAE model MOG in C57BL mice to the lipid GGG of PCT/GB2004/003524. GGPc shows excellent protection at 100 ul. It was tested at 4 doses (25, 50, 100 and 200 microL) against CCC (150 microL) and PEG (the diluant for GGPC) and as part of a very large study which included CGC (0134) and 884.

25 The dose response curve showed a significant effect ( $p < 0.050$  compared to CCC) at the 100 microL dose, but no effect at a higher dose of 200microL. The control EAE showed the disease was modelled well (max score of 3.5-4) and CGC (prior compounds of the inventors) was effective at 100 microL. This compared to 50 microL in previous studies where the disease state was less severe.

30 GGPc also showed bell shaped curve and provided protection/reduced severity at 100 ul of 50% phospholipid in PEG200 .By comparison high sn-2 Borage oil showed effect at 350ul.

### Measurement of PBMC cytokines

#### Isolation and Culture of PBMC

Heparinised whole blood was diluted with an equal volume of Hanks' balanced salt solution (Sigma, UK) and the resulting diluted blood layered onto  
5 Lymphoprep (Nycomed, Oslo, Norway). Following density centrifugation at 800g for 30 minutes the PBMC were removed from the interface and diluted in Hanks' solution. The cells were then washed twice by centrifugation for 10 minutes at 250g. The resulting final pellet was then resuspended in culture medium consisting of  
10 RPMI-1640 medium (Sigma, UK) supplemented with 2mM L-glutamine, 100U penicillin and 100µg streptomycin (Sigma, UK) and 10% autologous plasma.  $2 \times 10^6$  per ml PBMC, >95% viable as judged by trypan blue exclusion, were added to tissue culture tubes (Bibby Sterilin Ltd, Stone, UK) and incubated for 24h at 37°C with 5% CO<sub>2</sub>. The concentration of antigen, cell density and time of culture were all  
15 determined in previous kinetic experiments to determine maximum cytokine production (data not shown). Routine cytospin preparations were also prepared for subsequent differential counts. Following incubation the cells were removed from culture by centrifugation at 250g for 10 minutes, the resulting supernatants were then removed, aliquoted and stored at -70°C.

#### Preparation of Plasma Samples

20 10ml of heparinised blood was spun at 250g for 10 minutes. The resulting plasma layer was then removed, aliquoted and stored at -70°C.

#### Detection of Pro-inflammatory Cytokines

TNF- $\alpha$ , IL-1 $\beta$  and IFN- $\gamma$  in cell culture supernatants and plasma were detected using commercially available paired antibodies enabling cytokine detection in an ELISA  
25 format (R&D systems Ltd, Abingdon, UK). The sensitivities for the TNF- $\alpha$  and IFN- $\gamma$  ELISAs were 15.6-1000pg/ml and 3.9-250pg/ml for IL-1 $\beta$ .

#### Detection of Biologically Active TGF- $\beta$ 1

Biologically active TGF- $\beta$ 1 in cell culture supernatants and plasma were detected  
30 using the commercially available E<sub>max</sub> ELISA system with a sensitivity of 15.6-1000pg/ml (Promega, Southampton, UK).

Statistical Analysis

Differences in cytokine production were compared using Student's *t*-test and Mann-Whitney *U*-test and were considered significant when *p* values were less than 0.05.



CLAIMS.

1. A method of treating a patient in need of therapy for a disease in which cytokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterified with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of  $\gamma$ -linolenoyl, dihomogamma-linolenoyl acid and arachidonoyl.
2. A method as claimed in Claim 1 wherein the patient is in need of modulation of transforming growth factor  $\beta$  (TGF- $\beta$ ), particularly TGF- $\beta$ 1.
3. A method as claimed in Claim 1 or Claim 2 wherein the patient is in need of modulation of a cytokines selected from TNF- $\alpha$  and IL-1 $\beta$ .
4. A method as claimed in any one of the preceding claims wherein the patient is in need of therapy to maintain and/or restore cytokine balance where imbalance is found in diseases of the immune system and in neurodegeneration.
5. A method as claimed in any one of the preceding claims wherein the disease is an autoimmune disease or multiple sclerosis.
6. A method as claimed in any one of the preceding claims wherein the phospholipid has a fatty acyl group selected from the group consisting of  $\gamma$ -linolenoyl acid, dihomogamma-linolenoyl acid and arachidonoyl at only one of the sn-1 or sn-2 positions of the phosphatidyl group, the other position being free hydroxyl or esterified with a C2 to C36 unsaturated, monounsaturated or polyunsaturated fatty acyl group.
7. A method as claimed in any one of the preceding claims wherein the phospholipid has a an sn-1 position fatty acyl group selected from  $\gamma$ -linolenoyl,

dihomo- $\gamma$ -linolenoyl and arachidonoyl and an sn-2 position fatty acyl group selected from C2 to C36 unsaturated, monounsaturated or polyunsaturated fatty acyl other than n-6 acids.

5 8. A method as claimed in Claim 6 or 7 wherein the other fatty acid is such that it is used in the metabolic pool, eg. being unsaturated or a metabolically acceptable acid such as oleic or palmitic acid.

9. A method as claimed in any one of the preceding claims wherein the  
10 phospholipid phosphatidyl group is selected from those found in mammalian, particularly human, cell membranes,

10. A method as claimed in Claim 9 wherein the phosphatidyl group is selected from those consisting of phosphatidyl-choline, phosphatidyl-ethanolamine,  
15 phosphatidyl-serine, phosphatidyl- inositol, and plasmalogens of the above e.g. lyso-phosphatidyl-choline, lyso-phosphatidyl-ethanolamine, lyso- phosphatidyl- inositol and lyso-phosphatidyl- inositol.

11. A method as claimed in any one of the preceding claims wherein the patient is  
20 in need of treatment for a neurodegenerative disease involving demyelination.

12. A method as claimed in Claim 11 wherein the demyelination is arrested or reversed.

25 13. A method as claimed in Claim 11 or 12 wherein the treatment arrests underlying neurodegeneration and restores neuronal function.

14. A method as claimed in any one of Claims 11 to 13 wherein the method normalises membrane composition, in immune cells and/or neurones, and restores  
30 healthy PBMC spontaneously released TGF- $\beta$ 1/TNF $\alpha$  ratios and the ratios of TGF- $\beta$ 1 with other PBMC released cytokines.

15. A method as claimed in any one of the preceding claims wherein the treatment arrests neurodegeneration in multiple sclerosis.
16. A method as claimed in Claim 15 wherein the treatment is for a disease  
5 selected from the group consisting of relapsing remitting, primary and secondary progressive and other chronic progressive MS and the restoration, in part or completely, of neuronal function such as measured, eg. By MRI or CAT scan or by EDSS score.
- 10 17. A method as claimed in Claim 16 wherein the EDSS score preferably is improved by at least one point, more preferably at least 1.5 points and most preferably by at least 2 points over 18 months of daily treatment.
18. A method as claimed in any one of the preceding claims wherein the treatment  
15 is selected from the group of those for cerebral impairment after stroke, head trauma and intracranial bleeding where there is demyelination or neuronal damage.
19. A method as claimed in any one of the preceding claims wherein the treatment is for chronic demyelination such as in Alzheimer's and Parkinson's disease.
- 20 20. A method as claimed in any one of the preceding claims wherein the phospholipid is administered for a duration and at a dose sufficient to maintain or elevate TGF- $\beta$ 1 levels in the patient to therapeutic levels.
- 25 21. A method as claimed in Claim 20 wherein the therapeutic levels is that at least consistent with healthy subjects.
22. A method as claimed in Claim 20 or 21 wherein the dose is such as to produce a TGF- $\beta$ 1/TNF- $\alpha$  ratio spontaneously released from peripheral blood mononuclear  
30 cells (PBMCs) isolated from blood of a patient, after 18 months of daily dosing, of 0.4 to 3.0.


23. A method as claimed in Claim 21 or 22 wherein the level of TGF- $\beta$ 1 spontaneously released from the PBMCs is at least 80pg/ml  $2 \times 10^6$  cells.

24. A method as claimed in Claim 23 wherein the level of TGF- $\beta$ 1 released is above 100pg/ml and most preferably above 140pg/ml, still more preferably greater than 180pg/ml.

25. A method as claimed in any one of the preceding claims wherein the amount of phospholipid administered daily is between 1 and 30 grams, orally dosed.

10

26. A method as claimed in any one of the preceding claims wherein the phospholipid is a monoacyl or diacylphosphoglyceride, containing the at least one sn-1 or sn-2  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl or arachidonoyl group, and is of general Formula I



15

Formula I

wherein  $\text{R}^1$  and  $\text{R}^2$  are independently selected from the group consisting of hydrogen,  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl and arachidonoyl, mono-unsaturated acyl, linoleoyl or n-3 polyunsaturated acyl groups and optionally substituted  $\text{C}_{2-36}$  saturated acyl, and

$\text{R}^3$  is selected from moieties that are conjugated to phosphatidyl groups naturally occurring in mammalian membranes

with the condition that one of  $\text{R}^1$  and  $\text{R}^2$  must be selected from  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl and arachidonoyl.

25

27. A method as claimed in Claim 26 wherein the acyl groups  $R^1$  and  $R^2$ , when they are not  $\gamma$ -linolenoyl, dihomogamma-linolenoyl and arachidonoyl, are saturated fatty acyl of formula  $-\text{CO}-(\text{CH}_2)_n-\text{CH}_3$ , wherein  $n$  is an integer selected from 1 to 22, more preferably being 4 to 16, still more preferably being from 5 to 12, most preferably being from 6 to 10.
28. A method as claimed in Claim 27 wherein the acyl groups are those of caprylic and capric acids, particularly being 1,3-dicaprylic or 1,3-dicapric glycerols
29. A method as claimed in Claim 26 wherein the group  $R^3$  is a polar group selected from the group consisting of choline, ethanolamine, serine, inositol and glycerol.
30. A method as claimed in Claim 26 wherein the group  $R^3$  is a bipolar group selected from substituted  $\text{C}_{1-10}$  alkyl or alkenyl groups substituted with eg amine, hydroxy or thio at one end and hydroxyl at the other such that there is formed a phosphotidate ester with the polar group.
31. A method as claimed in any one of Claims 6 to 30 wherein the non-obligate sn-1 and sn-2 fatty acyl chain ( $R^1$  and  $R^2$ ) is unsaturated and may also be that of other essential fatty acids, such as the n-3 acids such as stearidonic acid, eicosapentanoic acid and docosahexanoic acid.
32. A method as claimed in any one of the Claims 6 to 31 is optionally substituted by hydroxy, oxo, carboxyl, alkyl, alkenyl and alkoxy groups.
33. Use of a compound of formula I, as defined in any one of claims 1 to 32 for the manufacture of a medicament for the treatment of disease in which cytokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit.
34. A pharmaceutical composition for the treatment of a patient in need for modulation of dysregulated cytokines or cytokines which are otherwise capable of

modulation to provide therapeutic benefit characterised in that it comprises a phospholipid comprising a phosphatidyl group esterified with one or more fatty acyl groups, characterised in that the lipid has a fatty acyl at the sn-1 and/or sn-2 position of the phosphatidyl group selected from the group consisting of  $\gamma$ -linolenoyl, dihomo-  
5  $\gamma$ -linolenoyl acid and arachidonoyl.

35. A composition as claimed in Claim 34 for treating neurodegenerative conditions, particularly those such as demyelinating diseases, such as multiple sclerosis, Alzheimer's and Parkinsons diseases and the degenerative sequelae  
10 associated with head trauma, stroke and intracranial bleeds, whereby neuronal function may be improved or restored from an impaired condition, eg. by remyelination.

36. A composition as claimed in Claim 34 or 35 comprising the pure  
15 phospholipids.

37. A composition as claimed in any one of Claims 34 to 36 wherein the phospholipid is mixed or otherwise together with a diluent or carrier material.

20 38. A composition as claimed in any one of Claims 34 to 37 wherein the diluent or carrier is a polymer.

39. A composition as claimed in Claim 38 wherein the diluent or carrier is polyethylene glycol.  
25

40. A composition as claimed in Claim 39 wherein the diluent or carrier is PEG200.


41. A composition as claimed in any one of claims 34 to 40 wherein the diluent or  
30 carrier is present at amounts between 1 and 99% diluent or carrier to 99% to 1% by weight of phospholipid.

42. A composition as claimed in Claim 41 wherein the diluent or carrier is present at between 20 to 80% diluent or carrier to 80 to 20% of phospholipid and more preferably 40 to 60% diluent or carrier to 60 to 40% by weight of phospholipid.

5 43. A composition as claimed in any one of Claims 34 to 42 further comprising a further therapeutic agent for said disease.

44. A composition as claimed in Claim 43 wherein the further therapeutic agent is selected from an ion channel blockers, an interferons ( $\alpha$ ,  $\beta$ , or  $\gamma$ ), a T-cell depleter and  
10 a steroid.

45. A phospholipid selected from monoacyl or diacylphosphatidyl compounds of general formula 1 containing at least one  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl or arachidonoyl group



15

Formula I

wherein  $\text{R}^1$  and  $\text{R}^2$  are independently selected from the group consisting of hydrogen,  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl and arachidonoyl, mono-unsaturated fatty acyl, linoleoyl, n-3 polyunsaturated acyl groups and optionally substituted  $\text{C}_{2-36}$  saturated acyl, and  
20

$\text{R}^3$  is selected from moieties that are found conjugated to phosphatidyl groups in mammalian cell membranes

with the condition that ONLY one of  $\text{R}^1$  and  $\text{R}^2$  MUST be selected from  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl acid and arachidonoyl and the other is not one of these fatty acid  
25 residues.

46. A phospholipid as claimed in Claim 45 wherein the acyl groups  $R^1$  and  $R^2$ , when they are not  $\gamma$ -linolenic acid, dihomogamma-linolenic acid and arachidonic acid, are saturated acid moieties, preferably fatty acids, of formula  $-\text{CO}-(\text{CH}_2)_n-\text{CH}_3$ , wherein n is an integer selected from 1 to 22, more preferably being 4 to 16, still more preferably being from 5 to 12, most preferably being from 6 to 10. Particularly preferred acyl groups are those of caprylic and capric acids, particularly being 1,3-dicaprylic or 1,3-dicapric glycerols having the  $\gamma$ -linolenic acid, dihomogamma-linolenic acid or arachidonic acid moiety at the sn-1 or sn-2 position, most preferably the sn-1 position.

47. A phospholipid as claimed in Claim 45 or 46 wherein the group  $R^3$  is selected from choline, ethanolamine, serine, inositol and glycerol.

48. A phospholipid as claimed in any one of Claims 45 to 47 wherein the non-obligate sn-1 and sn-2 is selected from fatty acids that are metabolised in the human to yield energy as opposed to a fatty acid that is primarily directed to the structural membrane pool.

49. A method of synthesis A preferred exemplary known phospholipid for use in the method, composition and use of the invention *1,2-Di( $\gamma$ -linolenyl)-sn-glycerophosphocholine* GGPc.

50. A method of preparation of compounds selected from the group consisting of GGPc, DHGLA-DHGLA-Pc and AAPc in a one step process comprising reaction of sn-glycerophosphocholine cadmium complex with  $\gamma$ -linolenic, dihomogamma-linolenic, or arachidonic anhydride

51. A method as claimed in claim 50 comprising freeze-drying a dioxan solution of the crude product gave a white solid.

52. A method of preparation of compounds selected from the group consisting of GGPc, DHGLA-DHGLA-Pc and AAPc comprising reacting sn-



glycerophosphocholine cadmium complex with a fatty acid selected from the group consisting of  $\gamma$ -linolenic imidazolide, dihomogamma-linolenic imidazolide and arachidonoyl imidazolide in the presence of dimethyl sodium in polar solvent.


5 53. A method of preparation as claimed in claim 52 wherein the polar solvent is DMSO.

54. A method of preparation of compounds selected from the group consisting of GGPc, DHGLA-DHGLA-Pc and AAPc comprising reacting 1-trityl-sn-  
10 glycerophosphocholine with one of  $\gamma$ -linolenic anhydride,  $\gamma$ -linolenic chloride, dihomogamma-linolenic anhydride, dihomogamma-linolenic chloride and arachidonoyl anhydride chloride or arachidonoyl anhydride.

55. A method as claimed in Claim 54 wherein the sodium salt of TritylPc is  
15 acylated with decanoyl imidazolide, the trityl group removed and residue acylated at the 1-hydroxyl group with the n-6 anhydride or chloride.


1/5

Fig. 1.

1-Decanoyl-2-octadeca-6Z,9Z,12Z<sub>42</sub>-trienoyl-sn-glycero-3-phosphocholineC<sub>36</sub>H<sub>66</sub>NO<sub>8</sub>P M.Wt.671.9

2/5

Fig.2.




1-decanoyl-2-octadeca-6Z,9Z,12Z-trienoyl-sn-glycero-3-phosphocholine

 $\text{C}_{36}\text{H}_{66}\text{NO}_8\text{P}$  M.Wt.671.9

3/5

Fig.3.




2-Decanoyl-1-octadeca-6Z,9Z,12Z-trienoyl-sn-glycero-3-phosphocholine

 $\text{C}_{36}\text{H}_{66}\text{NO}_8\text{P}$  M.Wt.671.9

4/5

Fig.4.




2-decanoyl-1-octadeca-6Z,9Z,12Z-trienoyl-sn-glycero-3-phosphocholine

$$\text{C}_{36}\text{H}_{66}\text{NO}_8\text{P} \quad \text{M.Wt.671.9}$$

5/5

Fig.5.

Route to 1,2-Di( $\gamma$ -linolenoyl)-sn-glycero-3-phosphocholine (GGPc)

1,2-Di(octadeca-6Z,9Z,12Z-trienoyl)-sn-glycero-3-phosphocholine  
 $\text{C}_{44}\text{H}_{76}\text{NO}_8\text{P}$  M.Wt. = 778.1

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 June 2006 (01.06.2006)

PCT

(10) International Publication Number  
**WO 2006/056783 A3**

(51) International Patent Classification:

A61K 31/683 (2006.01) A61P 25/28 (2006.01)  
A61K 31/685 (2006.01) A61P 25/16 (2006.01)  
A61P 37/02 (2006.01)

(74) Agent: DOLAN, Anthony, Patrick; BTG INTERNATIONAL LIMITED, 10 Fleet Street, Limeburner Lane, London EC4M 7SB (GB).

(21) International Application Number:

PCT/GB2005/004516

(22) International Filing Date:

25 November 2005 (25.11.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0425932.1 25 November 2004 (25.11.2004) GB

(81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): BTG INTERNATIONAL LIMITED [GB/GB]; 10 Fleet Place, Limeburner Lane, London EC4M 7SB (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HARBIGE, Laurence, S. [GB/GB]; The University of Greenwich, Woolwich Campus, Wellington Street, London SE18 6PF (GB). LEACH, Michael, J. [GB/GB]; The University of Greenwich, Woolwich Campus, Wellington Street, London SE18 6PF (GB). SHARIEF, Mohammed [GB/GB]; Dept. of Clinical Neurosciences, Guy's, King's & St Thomas's School of Medicine, Hodgkin Building, Guy's Hospital, London SE1 9RT (GB). BARRACLOUGH, Paul [GB/GB]; 27 Sevington Park, Maidstone, Kent ME15 9SB (GB).

Published:

— with international search report

(88) Date of publication of the international search report:

1 March 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STRUCTURED PHOSPHOLIPIDS FOR TREATING AUTOIMMUNE AND NEURODEGENERATIVE DISEASES

(57) Abstract: A method of treating a patient in need of therapy for a disease in which cytokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterified with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of  $\gamma$ -linolenoyl, dihomo- $\gamma$ -linolenoyl acid and arachidonoyl.

WO 2006/056783 A3

# INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2005/004516

## A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/683 A61K31/685 A61P37/02 A61P25/28 A61P25/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, CHEM ABS Data, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 622 180 A (PALTAUF ET AL) 11 November 1986 (1986-11-11) cited in the application examples 13,24 -----	45-48
X	US 2003/045460 A1 (FOGELMAN ALAN M ET AL) 6 March 2003 (2003-03-06) claim 19 -----	45-48
X	EP 0 609 078 A (SCOTIA HOLDINGS PLC) 3 August 1994 (1994-08-03) cited in the application page 3, lines 5-52 page 12, line 36 - page 13, line 57 claims 1-8 ----- -/--	34-42, 45-48

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

21 August 2006

Date of mailing of the international search report

-1 12. 2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Bazzanini, Rita



## INTERNATIONAL SEARCH REPORT

International application No  
PCT/GB2005/004516

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 505 817 A (FIDIA S.P.A) 30 September 1992 (1992-09-30)  page 2, lines 1-43 page 3, lines 50-54 page 5, lines 15-49 page 6, lines 1-27 page 15, lines 53-57 claims 1-6,13,22-30 -----	1-17, 20-42, 45-48
X	PATENT ABSTRACTS OF JAPAN vol. 1995, no. 01, 28 February 1995 (1995-02-28) & JP 06 279311 A (SAGAMI CHEM RES CENTER; others: 01), 4 October 1994 (1994-10-04) abstract -----	1-6, 8-14, 19-27, 29-42, 45-48
X	PATENT ABSTRACTS OF JAPAN vol. 1996, no. 03, 29 March 1996 (1996-03-29) & JP 07 309773 A (SAGAMI CHEM RES CENTER; others: 01), 28 November 1995 (1995-11-28) abstract -----	1-6, 8-14, 19-27, 29-42, 45-48

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2005/004516

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 49-55 because relating to a separate invention  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
34-42 (all partially), 1-33, 45-48

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-33 (completely), 34-42 (partially), 45-48 (completely)

First and second medical use of a phospholipid as defined in claim 1 and by formula (I) ALONE for treating a disease in which cytokines have become dysregulated, i.e. diseases of the immune system (autoimmune diseases) or neurodegeneration, such as multiple sclerosis; cerebral impairment after stroke, head trauma and intracranial bleeding where there is demyelination or neuronal damage; Alzheimer's and Parkinson's disease. Phospholipids of formula (I), as defined in claims 45-48, "per se".

---

2. claims: 34-42 (partially), 43-44 (completely)

First medical use of a phospholipid as defined in claim 34 and by formula (I) IN COMBINATION with a further therapeutic agent selected from an ion channel blocker, an interferon, a T-cell depleter or a steroid, for treating a disease in which cytokines have become dysregulated, i.e. neurodegenerative diseases, and particularly demyelinating diseases such as multiple sclerosis, Alzheimer's and Parkinson's disease, and the degenerative sequelae of stroke, head trauma and intracranial bleeding.

---

3. claims: 49-55 (all completely)

Method of preparation of GGPC, DHGLA-DHGLA-Pc and AAPc.

---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2005/004516

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4622180	A	11-11-1986	AT 383130 B	25-05-1987
			AT 159084 A	15-10-1986
			AU 565316 B2	10-09-1987
			AU 4244885 A	21-11-1985
			BR 8502293 A	21-01-1986
			CA 1244462 A1	08-11-1988
			DD 233130 A1	19-02-1986
			DD 245668 A1	13-05-1987
			DE 3563533 D1	04-08-1988
			DK 98192 A	03-08-1992
			DK 212185 A	16-11-1985
			EP 0161519 A2	21-11-1985
			ES 8603899 A1	16-05-1986
			ES 8603900 A1	16-05-1986
			FI 851781 A	16-11-1985
			HU 39454 A2	29-09-1986
			HU 203555 B	28-08-1991
			IE 58511 B1	06-10-1993
			IL 75133 A	30-12-1988
			JP 1794020 C	14-10-1993
			JP 4082157 B	25-12-1992
			JP 60252490 A	13-12-1985
			NO 851928 A	18-11-1985
			NZ 212067 A	28-10-1988
			PH 21831 A	17-03-1988
			PH 23978 A	09-02-1990
			SU 1400511 A3	30-05-1988
			SU 1422999 A3	07-09-1988
			TR 22204 A	24-09-1986
			US 4717512 A	05-01-1988
			YU 81585 A1	31-10-1987
			YU 81685 A1	31-10-1987
			ZA 8503697 A	29-01-1986
US 2003045460	A1	06-03-2003	AU 8673201 A	04-03-2002
			CA 2420222 A1	28-02-2002
			CN 1469754 A	21-01-2004
			CN 1739787 A	01-03-2006
			EP 1318828 A1	18-06-2003
			JP 3822167 B2	13-09-2006
			JP 2004506693 T	04-03-2004
			JP 2006056899 A	02-03-2006
			WO 0215923 A1	28-02-2002
			US 6664230 B1	16-12-2003
EP 0609078	A	03-08-1994	AU 671329 B2	22-08-1996
			AU 5474994 A	04-08-1994
			CA 2114349 A1	28-07-1994
			CN 1097124 A	11-01-1995
			JP 6293785 A	21-10-1994
			NO 940288 A	28-07-1994
			NZ 250768 A	21-12-1995
			SG 49749 A1	15-06-1998
			US 5466841 A	14-11-1995
			ZA 9400587 A	09-09-1994
EP 0505817	A	30-09-1992	CA 2063039 A1	16-09-1992
			IT 1247165 B	12-12-1994

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2005/004516

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0505817	A	JP 5124978 A	21-05-1993
JP 06279311	A	04-10-1994	NONE
JP 07309773	A	28-11-1995	NONE